Impax Labs' Digoxin ANDA: Analyzing the Discontinued Generic and Ongoing Regulatory Activity
Impax Labs' ANDA078556 for generic Digoxin (0.125MG, 0.25MG tablets) received original approval on July 20, 2009, but its products are now discontinued. This analysis details the regulatory history, including a recent labeling approval on February 9, 2026, and its implications for procurement and supply chain resilience, emphasizing the need for alternative sourcing strategies for this critical cardiac glycoside.
Approval Summary: Impax Labs' Discontinued Digoxin ANDA Approval
ChemLifeIntel's analysis confirms that Impax Labs, operating as the sponsor for application number ANDA078556, secured original approval for its generic Digoxin formulation on July 20, 2009. This approval covered oral tablet dosages of 0.125MG and 0.25MG, both classified as human prescription drugs intended for oral administration. Digoxin is a well-established cardiac glycoside, a critical therapeutic agent used in the management of heart conditions. However, a crucial detail for procurement directors and supply chain VPs is that both the 0.125MG and 0.25MG products under this specific ANDA are currently listed with a 'Discontinued' marketing status. This means that while the regulatory approval for these generic versions by Impax Labs (with Amneal Pharmaceuticals of New York LLC listed as a manufacturer) remains on record, these specific products are not actively being supplied to the market from this particular application. This necessitates a proactive review of existing Digoxin sourcing strategies to ensure continuity of supply from active manufacturers.
Market Dynamics: Impact of Impax Labs' Digoxin Discontinuation
The discontinuation of Impax Labs' 0.125MG and 0.25MG Digoxin tablets under ANDA078556 significantly alters the competitive landscape for this essential cardiac glycoside. For procurement directors, this means that the market no longer benefits from the supply volume or pricing pressure that these specific generic products might have exerted. While the original approval in 2009 would have introduced generic competition, their subsequent discontinuation removes a participant from active market supply. This situation could lead to shifts in market share among remaining active generic and brand-name Digoxin suppliers. Business development executives should view this as an opportunity to assess the current market for Digoxin, identify existing supply gaps, and potentially position their own active generic offerings. Supply chain VPs must ensure robust contingency plans are in place, verifying that their current Digoxin sourcing is diversified and not reliant on discontinued products, thereby mitigating potential supply disruptions for this vital medication.
Regulatory Trajectory: Sustained Labeling Approvals for ANDA078556
Despite the 'Discontinued' status of the specific Digoxin products under ANDA078556, Impax Labs has maintained an active regulatory profile for this application, particularly concerning labeling updates. The application has seen numerous supplemental approvals for labeling, with the most recent one occurring on February 9, 2026 (submission number 26). Other significant labeling approvals include November 12, 2020 (submissions 13, 18, 21, 22), April 6, 2015 (submissions 5, 10), and April 26, 2010 (submission 2). This consistent regulatory activity, even for discontinued products, is a critical point for regulatory affairs heads. It underscores the ongoing compliance obligations associated with an approved ANDA, regardless of active marketing status. Maintaining updated labeling ensures that should the products ever be relaunched or transferred, they adhere to the latest regulatory standards. This also highlights the long-term regulatory burden and commitment required for generic drug approvals, even when commercialization strategies evolve.
Supply Chain Resilience: Sourcing Considerations for Digoxin
Given the discontinuation of Impax Labs' specific Digoxin products (0.125MG and 0.25MG tablets) under ANDA078556, procurement directors must prioritize a thorough review of their current Digoxin sourcing strategies. The absence of these specific generic options from the active market underscores the importance of a resilient and diversified supply chain for critical cardiac glycosides. Organizations should identify and validate all active manufacturers and suppliers of Digoxin to ensure uninterrupted access to this essential medication. This involves assessing supplier capacity, regulatory compliance, and geographical diversification to mitigate risks associated with single-source reliance or unexpected product discontinuations. Business development executives should also monitor the market for any new ANDA approvals or product launches for Digoxin that could introduce new supply options or alter pricing dynamics. Proactive engagement with alternative suppliers is paramount to safeguard against potential shortages and maintain patient access to Digoxin.
Strategic Implications for Pharmaceutical Stakeholders
The case of Impax Labs' Digoxin ANDA078556 offers several strategic lessons for senior decision-makers across the global chemical and life sciences industry. For supply chain VPs, it emphasizes that regulatory approval does not guarantee perpetual market presence; continuous monitoring of product marketing status is essential. The ongoing labeling approvals, even for discontinued products, signal a sustained regulatory commitment that regulatory affairs heads must manage, potentially impacting resource allocation for compliance. Business development executives should analyze such discontinuations not just as market withdrawals but as opportunities for other active generic manufacturers to expand their market share for Digoxin. Furthermore, the event reinforces the broader imperative for procurement directors to cultivate robust supplier relationships and maintain a comprehensive understanding of the entire product lifecycle, from initial approval to potential discontinuation, to ensure the uninterrupted supply of critical medications like Digoxin. This proactive approach is vital for navigating the complexities of the generic pharmaceutical market.